{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:54:04Z","timestamp":1789685644033,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The mortality rate of patients with unresectable gastric cancer (UGC) has decreased with the development of chemotherapies and surgical techniques. However, the survival rate remains low. We retrospectively examined the prognostic significance of the pretreatment skeletal muscle mass index (SMI) and nutritional and inflammatory factors in patients with UGC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study included 83 patients diagnosed with UGC at Tottori University Hospital who received palliative chemotherapy based on 5-fluorouracil. Pretreatment computed tomography (CT) measured overall skeletal muscle mass (SMM) and cross-sectional SMM at the third lumbar vertebra (L3). We focused on the neutrophil-to-lymphocyte ratio (NLR), C-reactive protein-to-albumin ratio (CAR), prognostic nutritional index (PNI), and platelet-to-lymphocyte ratio (PLR) as nutritional and inflammatory factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Receiver operating characteristic curve analysis was performed for median survival time (MST) after palliative chemotherapy. SMIs for males and females (43.9\u2009cm<jats:sup>2<\/jats:sup>\/m<jats:sup>2<\/jats:sup> and 34.7\u2009cm<jats:sup>2<\/jats:sup>\/m<jats:sup>2<\/jats:sup>, respectively) were the cutoff values, and patients were divided into high (SMI<jats:sup>High<\/jats:sup>; <jats:italic>n<\/jats:italic>\u2009=\u200941) and low SMI groups (SMI<jats:sup>Low<\/jats:sup>; <jats:italic>n<\/jats:italic>\u2009=\u200942). Body mass index (BMI) was significantly higher in patients in the SMI<jats:sup>High<\/jats:sup> group than in the SMI<jats:sup>Low<\/jats:sup> group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The number of patients who received third-line chemotherapy was significantly higher in the SMI<jats:sup>High<\/jats:sup> group than in the SMI<jats:sup>Low<\/jats:sup> group (<jats:italic>p<\/jats:italic>\u2009=\u20090.037). The MST was significantly higher in the SMI<jats:sup>High<\/jats:sup> group than in the SMI<jats:sup>Low<\/jats:sup> group (17.3 vs. 13.8\u2009months; <jats:italic>p<\/jats:italic>\u2009=\u20090.008). The incidence of grade 3 or 4 side effects was significantly higher in patients with SMI<jats:sup>Low<\/jats:sup> UGC (<jats:italic>p<\/jats:italic>\u2009=\u20090.028). NLR was significantly higher in patients with SMI<jats:sup>Low<\/jats:sup> than it was in those with SMI<jats:sup>High<\/jats:sup>. (<jats:italic>p<\/jats:italic>\u2009=\u20090.047). In the univariate analysis, performance status, SMI, histological type, lines of chemotherapy, and NLR were prognostic indicators. The multivariate analysis identified SMI (<jats:italic>p<\/jats:italic>\u2009=\u20090.037), NLR (<jats:italic>p<\/jats:italic>\u2009=\u20090.002), and lines of chemotherapy (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) as independent prognostic factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The SMI<jats:sup>Low<\/jats:sup> group had significantly more grade 3 or 4 side effects, were related to high NLR, and had a significantly worse prognosis than the SMI<jats:sup>High<\/jats:sup> group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Retrospectively registerd.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08953-8","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T13:02:42Z","timestamp":1636808562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil"],"prefix":"10.1186","volume":"21","author":[{"given":"Tomoyuki","family":"Matsunaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Miyauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Shishido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Miyatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Hanaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoichi","family":"Kihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruo","family":"Tokuyasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhisa","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimichi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,13]]},"reference":[{"issue":"6","key":"8953_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"issue":"44","key":"8953_CR2","doi-asserted-by":"publisher","first-page":"16750","DOI":"10.3748\/wjg.v20.i44.16750","volume":"20","author":"ZH Zou","year":"2014","unstructured":"Zou ZH, Zhao LY, Mou TY, Hu YF, Yu J, Liu H, et al. Laparoscopic vs open D2 gastrectomy for locally advanced gastric cancer: a meta-analysis. World J Gastroenterol. 2014;20(44):16750\u201364. https:\/\/doi.org\/10.3748\/wjg.v20.i44.16750.","journal-title":"World J Gastroenterol"},{"issue":"8","key":"8953_CR3","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.3748\/wjg.v22.i8.2403","volume":"22","author":"A Digklia","year":"2016","unstructured":"Digklia A, Wagner AD. Advanced gastric cancer: current treatment landscape and future perspectives. World J Gastroenterol. 2016;22(8):2403\u201314. https:\/\/doi.org\/10.3748\/wjg.v22.i8.2403.","journal-title":"World J Gastroenterol"},{"key":"8953_CR4","doi-asserted-by":"publisher","unstructured":"Li Z, Shan F, Ying X, Zhang Y, E JY, Wang Y, Ren H, Su X, Ji J: assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric Cancer: a randomized clinical trial. JAMA Surg 2019, 154(12):1093\u20131101, DOI: https:\/\/doi.org\/10.1001\/jamasurg.2019.3473.","DOI":"10.1001\/jamasurg.2019.3473"},{"issue":"1","key":"8953_CR5","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1186\/s12885-019-6294-9","volume":"19","author":"X Guo","year":"2019","unstructured":"Guo X, Zhao F, Ma X, Shen G, Ren D, Zheng F, et al. A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer. 2019;19(1):1125. https:\/\/doi.org\/10.1186\/s12885-019-6294-9.","journal-title":"BMC Cancer"},{"issue":"3","key":"8953_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215\u201321. https:\/\/doi.org\/10.1016\/S1470-2045(08)70035-4.","journal-title":"Lancet Oncol"},{"key":"8953_CR7","doi-asserted-by":"publisher","unstructured":"Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer 2021, 24(1):1\u201321, DOI: https:\/\/doi.org\/10.1007\/s10120-020-01042-y.","DOI":"10.1007\/s10120-020-01042-y"},{"issue":"9742","key":"8953_CR8","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","journal-title":"Lancet"},{"issue":"8","key":"8953_CR9","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.21873\/anticanres.14429","volume":"40","author":"Y Kanazawa","year":"2020","unstructured":"Kanazawa Y, Yamada T, Kakinuma D, Matsuno K, Ando F, Fujita I, et al. Skeletal muscle mass depletion after gastrectomy negatively affects the prognosis of patients with gastric Cancer. Anticancer Res. 2020;40(8):4271\u20139. https:\/\/doi.org\/10.21873\/anticanres.14429.","journal-title":"Anticancer Res"},{"issue":"5","key":"8953_CR10","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.21873\/anticanres.13340","volume":"39","author":"K Kuwada","year":"2019","unstructured":"Kuwada K, Kuroda S, Kikuchi S, Yoshida R, Nishizaki M, Kagawa S, et al. Clinical impact of sarcopenia on gastric Cancer. Anticancer Res. 2019;39(5):2241\u20139. https:\/\/doi.org\/10.21873\/anticanres.13340.","journal-title":"Anticancer Res"},{"issue":"4","key":"8953_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/SPC.0000000000000011","volume":"7","author":"S Antoun","year":"2013","unstructured":"Antoun S, Borget I, Lanoy E. Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer. Curr Opin Support Palliat Care. 2013;7(4):383\u20139. https:\/\/doi.org\/10.1097\/SPC.0000000000000011.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"3","key":"8953_CR12","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1158\/1078-0432.CCR-16-0940","volume":"23","author":"SS Shachar","year":"2017","unstructured":"Shachar SS, Deal AM, Weinberg M, Nyrop KA, Williams GR, Nishijima TF, et al. Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast Cancer receiving Taxane-based chemotherapy. Clin Cancer Res. 2017;23(3):658\u201365. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0940.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"8953_CR13","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1007\/s00268-018-4527-8","volume":"42","author":"H Saito","year":"2018","unstructured":"Saito H, Kono Y, Murakami Y, Shishido Y, Kuroda H, Matsunaga T, et al. Prognostic significance of platelet-based inflammatory indicators in patients with gastric Cancer. World J Surg. 2018;42(8):2542\u201350. https:\/\/doi.org\/10.1007\/s00268-018-4527-8.","journal-title":"World J Surg"},{"issue":"34","key":"8953_CR14","doi-asserted-by":"publisher","first-page":"6261","DOI":"10.3748\/wjg.v23.i34.6261","volume":"23","author":"JH Chen","year":"2017","unstructured":"Chen JH, Zhai ET, Yuan YJ, Wu KM, Xu JB, Peng JJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23(34):6261\u201372. https:\/\/doi.org\/10.3748\/wjg.v23.i34.6261.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"8953_CR15","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/dote.12381","volume":"29","author":"K Harada","year":"2016","unstructured":"Harada K, Ida S, Baba Y, Ishimoto T, Kosumi K, Tokunaga R, et al. Prognostic and clinical impact of sarcopenia in esophageal squamous cell carcinoma. Dis Esophagus. 2016;29(6):627\u201333. https:\/\/doi.org\/10.1111\/dote.12381.","journal-title":"Dis Esophagus"},{"issue":"1","key":"8953_CR16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1152\/jappl.1998.85.1.115","volume":"85","author":"N Mitsiopoulos","year":"1998","unstructured":"Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol (1985). 1998;85(1):115\u201322.","journal-title":"J Appl Physiol (1985)"},{"issue":"6","key":"8953_CR17","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1152\/japplphysiol.00744.2004","volume":"97","author":"W Shen","year":"2004","unstructured":"Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985). 2004;97(6):2333\u20138.","journal-title":"J Appl Physiol (1985)"},{"issue":"12","key":"8953_CR18","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","volume":"31","author":"L Martin","year":"2013","unstructured":"Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539\u201347. https:\/\/doi.org\/10.1200\/JCO.2012.45.2722.","journal-title":"J Clin Oncol"},{"key":"8953_CR19","doi-asserted-by":"publisher","unstructured":"Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer.\u00a02011;14(2):113\u201323. https:\/\/doi.org\/10.1007\/s10120-011-0042-4.","DOI":"10.1007\/s10120-011-0042-4"},{"key":"8953_CR20","doi-asserted-by":"publisher","unstructured":"Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017, 20(1):1\u201319, DOI: https:\/\/doi.org\/10.1007\/s10120-016-0622-4.","DOI":"10.1007\/s10120-016-0622-4"},{"key":"8953_CR21","doi-asserted-by":"publisher","unstructured":"Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9). https:\/\/doi.org\/10.1093\/jnci\/dju244.","DOI":"10.1093\/jnci\/dju244"},{"issue":"3","key":"8953_CR22","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1245\/s10434-014-4048-0","volume":"22","author":"A Kinoshita","year":"2015","unstructured":"Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, et al. The C-reactive protein\/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol. 2015;22(3):803\u201310. https:\/\/doi.org\/10.1245\/s10434-014-4048-0.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"8953_CR23","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1007\/s00268-017-4400-1","volume":"42","author":"H Saito","year":"2018","unstructured":"Saito H, Kono Y, Murakami Y, Shishido Y, Kuroda H, Matsunaga T, et al. Prognostic significance of the preoperative ratio of C-reactive protein to albumin and neutrophil-lymphocyte ratio in gastric Cancer patients. World J Surg. 2018;42(6):1819\u201325. https:\/\/doi.org\/10.1007\/s00268-017-4400-1.","journal-title":"World J Surg"},{"issue":"9","key":"8953_CR24","first-page":"1001","volume":"85","author":"T Onodera","year":"1984","unstructured":"Onodera T, Goseki N. Kosaki G: [prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients]. Nihon Geka Gakkai Zasshi. 1984;85(9):1001\u20135.","journal-title":"Nihon Geka Gakkai Zasshi"},{"issue":"1","key":"8953_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s10120-018-0882-2","volume":"22","author":"SK Kamarajah","year":"2019","unstructured":"Kamarajah SK, Bundred J, Tan BHL. Body composition assessment and sarcopenia in patients with gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2019;22(1):10\u201322. https:\/\/doi.org\/10.1007\/s10120-018-0882-2.","journal-title":"Gastric Cancer"},{"issue":"1","key":"8953_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/mco.2020.2165","volume":"14","author":"K Kouzu","year":"2021","unstructured":"Kouzu K, Tsujimoto H, Sugasawa H, Ishibashi Y, Itazaki Y, Tsuchiya S, et al. Impact of postoperative reduced skeletal muscle on prognosis after recurrence in gastric cancer. Mol Clin Oncol. 2021;14(1):3. https:\/\/doi.org\/10.3892\/mco.2020.2165.","journal-title":"Mol Clin Oncol"},{"issue":"5","key":"8953_CR27","doi-asserted-by":"publisher","first-page":"957","DOI":"10.21037\/jgo.2019.05.07","volume":"10","author":"M Ueno","year":"2019","unstructured":"Ueno M, Doi A, Sunami T, Takayama H, Mouri H, Mizuno M. Delivery rate of patients with advanced gastric cancer to third-line chemotherapy and those patients' characteristics: an analysis in real-world setting. J Gastrointest Oncol. 2019;10(5):957\u201364. https:\/\/doi.org\/10.21037\/jgo.2019.05.07.","journal-title":"J Gastrointest Oncol"},{"issue":"2","key":"8953_CR28","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.2217\/fon-2019-0429","volume":"16","author":"A Rizzo","year":"2020","unstructured":"Rizzo A, Mollica V, Ricci AD, Maggio I, Massucci M, Rojas Limpe FL, et al. Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis. Future Oncol. 2020;16(2):4409\u201318. https:\/\/doi.org\/10.2217\/fon-2019-0429.","journal-title":"Future Oncol"},{"issue":"4","key":"8953_CR29","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/jcsm.12436","volume":"10","author":"S Kurk","year":"2019","unstructured":"Kurk S, Peeters P, Stellato R, Dorresteijn B, de Jong P, Jourdan M, et al. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients. J Cachexia Sarcopenia Muscle. 2019;10(4):803\u201313. https:\/\/doi.org\/10.1002\/jcsm.12436.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"8953_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000502613","volume":"98","author":"N Matsuura","year":"2020","unstructured":"Matsuura N, Motoori M, Fujitani K, Nishizawa Y, Komatsu H, Miyazaki Y, et al. Correlation between skeletal muscle mass and adverse events of neoadjuvant chemotherapy in patients with gastric Cancer. Oncology. 2020;98(1):29\u201334. https:\/\/doi.org\/10.1159\/000502613.","journal-title":"Oncology"},{"key":"8953_CR31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/bs.acr.2014.10.007","volume":"125","author":"AT Nies","year":"2015","unstructured":"Nies AT, Magdy T, Schwab M, Zanger UM. Role of ABC transporters in fluoropyrimidine-based chemotherapy response. Adv Cancer Res. 2015;125:217\u201343. https:\/\/doi.org\/10.1016\/bs.acr.2014.10.007.","journal-title":"Adv Cancer Res"},{"issue":"6","key":"8953_CR32","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/clpt.2013.172","volume":"94","author":"KE Caudle","year":"2013","unstructured":"Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, et al. Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013;94(6):640\u20135. https:\/\/doi.org\/10.1038\/clpt.2013.172.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"8953_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1046\/j.1365-2125.2002.01598.x","volume":"54","author":"M Gusella","year":"2002","unstructured":"Gusella M, Toso S, Ferrazzi E, Ferrari M, Padrini R. Relationships between body composition parameters and fluorouracil pharmacokinetics. Br J Clin Pharmacol. 2002;54(2):131\u20139. https:\/\/doi.org\/10.1046\/j.1365-2125.2002.01598.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"8953_CR34","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1080\/17512433.2017.1347503","volume":"10","author":"JJ Hopkins","year":"2017","unstructured":"Hopkins JJ, Sawyer MB. A review of body composition and pharmacokinetics in oncology. Expert Rev Clin Pharmacol. 2017;10(9):947\u201356. https:\/\/doi.org\/10.1080\/17512433.2017.1347503.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"12","key":"8953_CR35","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2319","volume":"3","author":"EMC Feliciano","year":"2017","unstructured":"Feliciano EMC, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Kwan ML, et al. Association of Systemic Inflammation and Sarcopenia with Survival in nonmetastatic colorectal Cancer: results from the C SCANS study. JAMA Oncol. 2017;3(12):e172319. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2319.","journal-title":"JAMA Oncol"},{"issue":"8","key":"8953_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161125","volume":"11","author":"EY Kim","year":"2016","unstructured":"Kim EY, Kim YS, Seo JY, Park I, Ahn HK, Jeong YM, et al. The relationship between sarcopenia and systemic inflammatory response for Cancer Cachexia in small cell lung Cancer. PLoS One. 2016;11(8):e0161125. https:\/\/doi.org\/10.1371\/journal.pone.0161125.","journal-title":"PLoS One"},{"issue":"5","key":"8953_CR37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/ans.15030","volume":"89","author":"SY Rho","year":"2019","unstructured":"Rho SY, Hwang HK, Chong JU, Yoon DS, Lee WJ, Kang CM. Association of preoperative total lymphocyte count with prognosis in resected left-sided pancreatic cancer. ANZ J Surg. 2019;89(5):503\u20138. https:\/\/doi.org\/10.1111\/ans.15030.","journal-title":"ANZ J Surg"},{"issue":"2","key":"8953_CR38","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.juro.2012.09.166","volume":"189","author":"S Saroha","year":"2013","unstructured":"Saroha S, Uzzo RG, Plimack ER, Ruth K, Al-Saleem T. Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma. J Urol. 2013;189(2):454\u201361. https:\/\/doi.org\/10.1016\/j.juro.2012.09.166.","journal-title":"J Urol"},{"issue":"3","key":"8953_CR39","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ccr.2009.06.017","volume":"16","author":"ZG Fridlender","year":"2009","unstructured":"Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: \"N1\" versus \"N2\" TAN. Cancer Cell. 2009;16(3):183\u201394. https:\/\/doi.org\/10.1016\/j.ccr.2009.06.017.","journal-title":"Cancer Cell"},{"issue":"6","key":"8953_CR40","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1053\/j.gastro.2010.01.058","volume":"138","author":"J Terzi\u0107","year":"2010","unstructured":"Terzi\u0107 J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138(6):2101\u20132114.e2105.","journal-title":"Gastroenterology"},{"issue":"1","key":"8953_CR41","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12877-018-1007-9","volume":"18","author":"YD Rong","year":"2018","unstructured":"Rong YD, Bian AL, Hu HY, Ma Y, Zhou XZ. Study on relationship between elderly sarcopenia and inflammatory cytokine IL-6, anti-inflammatory cytokine IL-10. BMC Geriatr. 2018;18(1):308. https:\/\/doi.org\/10.1186\/s12877-018-1007-9.","journal-title":"BMC Geriatr"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08953-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08953-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08953-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T01:03:03Z","timestamp":1636851783000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08953-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,13]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8953"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08953-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,13]]},"assertion":[{"value":"16 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with the Declaration of Helsinki and guidelines on Good Clinical Practice and was conducted with the approval of the institutional review board of our institution (Tottori University, number 20A243), and the informed consent requirement was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1219"}}